← All trials
NCT06622603
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2024
- Primary completion
- Apr 30, 2026
- Completion date
- Oct 14, 2026
- First posted
- Oct 2, 2024
- Last posted
- Oct 2, 2024
- Enrollment
- 59
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Seoul National UniversityLead sponsor
- Seoul National UniversitySponsor investigator
- Eulji UniversityCollaborator
- Seoul National UniversityOfficial
- Chungnam National UniversityCollaborator
- Seoul National UniversityCollaborator
- Seoul National UniversityCollaborator
- Gachon UniversityCollaborator
- Ajou UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.